Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ST14 | Q9Y5Y6 | 3/20 | 0.71 |
| ▸ | LTA4H | P09960 | 3/20 | 0.61 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.59 |
| ▸ | MAOB | P27338 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL922977 | 0.98 | ST14 (0.68) | ST14LTA4HLOXL2MAOBTSHR | |
| SCHEMBL4209153 | 0.90 | ST14 (0.85) | ST14LOXL2MAOB | |
| SCHEMBL20240287 | 0.89 | ST14 (0.63) | ST14LTA4HLOXL2MAOBPLA2G2A | |
| SCHEMBL27571222 | 0.89 | TAAR1 (0.75) | ST14LTA4HLOXL2MAOBPLA2G2A | |
| Toluene SCHEMBL28616552 | 0.86 | ST14 (0.59) | ST14LTA4HLOXL2MAOBPLA2G2A | |
| SCHEMBL1301847 | 0.85 | LOXL2 (0.58) | ST14LTA4HLOXL2MAOBTSHR | |
| SCHEMBL30150584 | 0.84 | MAOB (0.86) | ST14MAOBMAOA | |
| SCHEMBL15345491 | 0.84 | ST14 (0.57) | ST14LTA4HLOXL2MAOBTSHR | |
| SCHEMBL28006451 | 0.83 | ST14 (0.74) | ST14LOXL2MAOBTAAR1 | |
| Hydrochloric Acid SCHEMBL919885 | 0.83 | LOXL2 (0.57) | ST14LTA4HLOXL2MAOBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 452 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114478474-B | Amide compound and preparation method thereof | 中国科学院宁波材料技术与工程研究所 | 2023-06-30 | — | — | CN | claimed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| EP-2804865-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-23 | — | — | EP | claimed |
| CN-1933827-A | Use of methylene amide derivatives in cardiovascular disorders | APPLIED RESEARCH SYSTEMS (AN) | 2007-03-21 | — | — | CN | claimed |
| CN-1185108-C | Thermosensitive recording material | CIBA SC HOLDING AG (CH) | 2005-01-19 | — | — | CN | claimed |
| CN-1330593-A | Heat sensitive recording material | CIBA SC HOLDING AG (CH) | 2002-01-09 | — | — | CN | claimed |
| EP-4635568-A2 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA Pharmaceuticals Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250296935-A1 | Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase | CELLTAXIS LLC (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250283094-A1 | Modified Nucleosides | SOMALOGIC OPERATING CO., INC. (US) | 2025-09-11 | — | — | US | disclosed |
| EP-3672954-B1 | COMPOUNDS, SALTS THEREOF AND THEIR USE FOR THE TREATMENT OF DISEASES | ACADIA PHARM INC (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250197385-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARM INC (US) | 2025-06-19 | — | — | US | disclosed |
| US-20250171582-A1 | CURING AGENT COMPOSITION FOR THERMOSETTING RESIN, EPOXY RESIN COMPOSITION, AND FIBER-REINFORCED COMPOSITE MATERIAL | TEIJIN LIMITED (JP) | 2025-05-29 | — | — | US | disclosed |
| WO-2025067540-A1 | PYRAZOLOTRIAZINE AND PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | 中国科学院上海药物研究所 | 2025-04-03 | — | — | WO | disclosed |
| WO-1996009294-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-03-28 | — | — | WO | disclosed |
| US-5484831-A | STABILIZATION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1996-01-16 | — | — | US | disclosed |
| WO-1995021815-A1 | CYCLOBUTANE DERIVATIVES AND THEIR USE AS INHIBITORS OF PROTEIN FARNESYLTRANSFERASE AND SQUALENE SYNTHASE | ABBOTT LABORATORIES (US) | 1995-08-17 | — | — | WO | disclosed |
| EP-0666278-A2 | Polyphenylene ether resin composition | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1995-08-09 | — | — | EP | disclosed |
| WO-1995012572-A1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE | ABBOTT LABORATORIES (US) | 1995-05-11 | — | — | WO | disclosed |
| EP-0636124-A1 | 3,4-DIHYDRO-2H-1,2,4-BENZOTHIADIAZINE-1,1-DIOXIDE-3-CARBOXYLIC ACID DERIVATIVES, PREPARATION THEREOF AND DRUGS CONTAINING SAME | Aventis Pharma S.A. (FR) | 1995-02-01 | — | — | EP | disclosed |
| WO-1993021170-A1 | 3,4-DIHYDRO-2H-1,2,4-BENZOTHIADIAZINE-1,1-DIOXIDE-3-CARBOXYLIC ACID DERIVATIVES, PREPARATION THEREOF AND DRUGS CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1993-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296935-A1 | Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | ST14 3372/4885LTA4H 1/4885LOXL2 810/4885 |
| US-20250197385-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | SLC10A1, CYP27A1, CYP11B2 | ST14 2999/4885LTA4H 744/4885LOXL2 1837/4885 |
| US-20250283094-A1 | Modified Nucleosides | NT5C3B, PNP, TYMP | ST14 4138/4885LTA4H 3816/4885LOXL2 4458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.